Taken together, the epigenetic observations with respect to promoter methylation status strongly suggests differential plasticities to XAF1 upregulation as a response to adaptive resistance of MGMT-hyper and MGMT-hypo GBM cell lines. The gene discussed is XAF1; the disease is glioblastoma.